<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639740</url>
  </required_header>
  <id_info>
    <org_study_id>TRACE</org_study_id>
    <secondary_id>2017-004037-93</secondary_id>
    <nct_id>NCT03639740</nct_id>
  </id_info>
  <brief_title>Treat-to-target With Secukinumab in Axial Spondyloarthritis</brief_title>
  <acronym>TRACE</acronym>
  <official_title>TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Mikkel Østergaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Healthcare A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of reductions in MRI inflammation in the sacroiliac joints and spine from week 16
      to 24 in patients who at week 16 are in ASDAS remission (i.e. continue sc. secukinumab 150 mg
      monthly) vs. not in ASDAS remission (i.e. increase sc. secukinumab 300 mg monthly). ASDAS
      remission is defined as ASDAS inactive disease i.e. ASDAS&lt;1.3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose will be increased or maintained after predetermined intervals depending on remission</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a positive change in MRI-inflammation</measure>
    <time_frame>Comparison of week 16 and 24</time_frame>
    <description>Assessed with the sum of SPARCC MRI SIJ and spine inflammation indices</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission vs patients not in ASDAS (Ankylosing Spondylitis Disease Activity Score) remission.</measure>
    <time_frame>Comparison of week 16 and 24</time_frame>
    <description>as measured by remission (&lt;1.3) / not in ASDAS remission (&gt;1.3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ASDAS score (i.e. Ankylosing Spondylitis Disease Activity Score (ASDAS 0.6-7.0))</measure>
    <time_frame>Evaluated from week 0 to 16 and from week 16 to 24</time_frame>
    <description>as measured by changes in ASDAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI inflammation scores from week 0 to 16 and week 16 to 24, respectively.</measure>
    <time_frame>Week 0 to 16 and week 16 to 24</time_frame>
    <description>as measured by the SPARCC MRI SIJ and Spine Inflammation indices and the Canada-Denmark MRI system for a positive change in MRI inflammation in the spine as assessed with the Canada-Denmark MRI system for assessment of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in scores/anatomical location of MRI lesions in the spine</measure>
    <time_frame>week 16</time_frame>
    <description>as measured by the Canada-Denmark MRI system for assessment of inflammation, fat metaplasia, erosion, and new bone formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in scores/anatomical location of MRI lesions in the SIJs</measure>
    <time_frame>week 16</time_frame>
    <description>as measured by the SPARCC MRI SIJ Inflammation Index and SPARCC SIJ Structural Score (SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI inflammation</measure>
    <time_frame>week 16</time_frame>
    <description>as measured by the SPARCC (Spondyloarthritis Research Consortium of Canada) MRI sacroiliac joint and Spine Inflammation indices and the Canada-Denmark MRI system for assessment of inflammation assessed on cMRI (conventional MRI) i.e. on STIR (short tau inversion recovery) sequences on conventional and novel scan planes and on DWI (Diffusion-weighted imaging) sequences evaluated visually and based on regions of interest (ROIs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab 150 milligram [Cosentyx]</intervention_name>
    <description>For intervention description: see arm/group description</description>
    <arm_group_label>Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor</arm_group_label>
    <other_name>Secukinumab 300 milligram [Cosentyx]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of axial spondyloarthritis (axSpA) according to the ASAS (Assessment of
             Spondyloarthritis International Society) criteria and/or ankylosing spondylitis (AS)
             according to the modified New York criteria as judged by a spondyloarthritis (SpA)
             rheumatologist (regarding imaging in the criteria, see below).

          2. Active inflammation on MRI of the SIJs and/or spine as evaluated by a central SpA
             imaging expert and/or radiographic modified New York criteria fulfilled as judged by a
             central SpA imaging expert.

          3. Active disease defined as ASDAS ≥ 2.1 (ASDAS high disease activity).

          4. Total back pain as measured on a visual analogue scale (VAS) scale ≥ 4 0 mm (0-100 mm)
             at baseline.

          5. Clinical indication for a biologic drug as assessed by the treating physician.

          6. Patients should have received at least 2 different NSAIDs at the highest recommended
             dose for at least 2 weeks each with an inadequate response or failure to respond, or
             less if therapy had to be reduced due to intolerance, toxicity or contraindications.

          7. Patients on NSAIDs at inclusion should stay on a stable dose from at least 2 weeks
             before the baseline MRI scans are performed and to the week 24 visit.

          8. Patients on synthetic disease-modifying anti-rheumatic drugs (sDMARDs) at inclusion
             should stay on a stable dose from at least 4 weeks before initiation of secukinumab to
             the week 24 visit.

          9. Patient must be able to understand and communicate with the investigator and comply
             with the requirements of the study and must provide written, signed and dated informed
             consent before any study assessment is performed.

         10. Male or female patients at least 18 years and less than 70 years of age.

         11. Sufficient contraception for women.

         12. Age ≥18 to &lt;70 years.

         13. Capable of giving informed consent.

         14. Capable of complying with the examination programme of the protocol.

        Exclusion Criteria:

          1. Contraindications for secukinumab (described in protocol).

          2. Contraindication for TNF inhibitor (described in protocol).

          3. Contraindication for MRI (described in protocol).

          4. Previous exposure to secukinumab or other biologic drug directly targeting
             interleukin-17 or interleukin-17 receptor.

          5. Previous exposure to TNF inhibitor or drug targeting TNF.

          6. Previous exposure to other types of biological disease-modifying anti-rheumatic drugs
             (bDMARDs) than TNF inhibitor.

          7. Patients taking high-potency opioid analgesics (e.g. methadone, hydromorphone,
             morphine)

          8. Any change in the dose of oral corticosteroids in the last 8 weeks prior to the
             baseline visit or use of i.v. intramuscular or intra-articular corticosteroid during
             the last 8 weeks prior to the enrollment visit.

          9. Use of any investigational drug and/or devices within 4 weeks before randomization or
             a period of 5 half-lives of the investigational drug, whichever is longer.

         10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test.

         11. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using effective methods of contraception during the
             entire study or longer if required by locally approved prescribing information (e.g.
             20 weeks in EU).

         12. Known recent drug or alcohol abuse.

         13. Incapable of complying with the examination programme for physical or mental reasons.

         14. Failure to provide written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Østergaard, DMSc PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne J Pedersen, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel Østergaard, DMSc PhD MD</last_name>
    <phone>+45 38633015</phone>
    <email>mo@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sengül Seven, MD</last_name>
    <phone>+45 3863 3014</phone>
    <email>senguel.seven@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne G Loft, MS DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Frederiksberg</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bente Jensen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikkel Østergaard, MD PhD DMSc</last_name>
    </contact>
    <investigator>
      <last_name>Mikkel Østergaard, MD PhD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne J Pedersen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sengül Seven, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inge J Sørensen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kong Christian X´s Gigthospital</name>
      <address>
        <city>Gråsten</city>
        <zip>6300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Oliver Hendricks, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Gentofte</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ole R Madsen, MD PhD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Nordsjællands Hospital Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jesper Nørregaard, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Regionshospitalet Nordjylland, Hjørring</name>
      <address>
        <city>Hjørring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcin Kowalski, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk afdeling, Sjællands Universitetshospital, Køge</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bo Ejbjerg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hans C Horn, consultant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Regionshospitalet Silkeborg</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rene Østgaard, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Professor Mikkel Østergaard</investigator_full_name>
    <investigator_title>Professor, DMSc, PhD, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

